Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised trial
<p>Background: There has been a significant change in trials methodology for solid tumours, in response to our greater understanding of cancer biology. FOCUS4 is a phase II/III trial programme testing targeted agents in patients with advanced colorectal cancer (CRC) in molecularly stratified c...
| প্রধান লেখক: | , , , , , , , , , , , , , , , |
|---|---|
| বিন্যাস: | Journal article |
| প্রকাশিত: |
Elsevier
2017
|
| _version_ | 1826256948119470080 |
|---|---|
| author | Adams, R Brown, E Brown, L Butler, R Falk, S Fisher, D Kaplan, R Quirke, P Richman, S Samuel, L Seligmann, J Seymour, M Shiu, KK Wasan, H Wilson, R Maughan, T |
| author_facet | Adams, R Brown, E Brown, L Butler, R Falk, S Fisher, D Kaplan, R Quirke, P Richman, S Samuel, L Seligmann, J Seymour, M Shiu, KK Wasan, H Wilson, R Maughan, T |
| author_sort | Adams, R |
| collection | OXFORD |
| description | <p>Background: There has been a significant change in trials methodology for solid tumours, in response to our greater understanding of cancer biology. FOCUS4 is a phase II/III trial programme testing targeted agents in patients with advanced colorectal cancer (CRC) in molecularly stratified cohorts. Here we present the first results testing the hypothesis that combined Her 1,2,3 signal inhibition, using the tyrosine kinase inhibitor AZD8931, will control growth of ‘all wildtype’ tumours.</p><p> Methods: FOCUS4-D includes patients with newly diagnosed advanced or metastatic colorectal cancer whose tumour is BRAF, PIK3CA, KRAS & NRAS wildtype. Following 16 weeks of first-line therapy, patients with stable or responding tumours were randomised to oral AZD8931 (40mg bd) or placebo. Randomisation was done using minimisation with a random element of 20%, with minimisation factors were of randomising hospital site, site of primary tumour, WHO performance status, 16-week CT scan result, number of metastatic sites, and first-line chemotherapy regimen. The primary outcome was progression-free-survival (PFS) according to RECIST v1.1 criteria, pre-specified to be analysed by intention-to-treat. Pre-planned interim analyses were agreed using MAMS trial design methodology triggered by occurrence of PFS events in the placebo group. This trial is registered, number ISRCTN 90061546.</p><p> Results: 32 patients were randomised between 01/2014 and 03/2016. Patients were balanced for baseline characteristics. At the first pre-planned interim analysis, the IDMC recommended closure of FOCUS4-D on grounds of lack of activity. At final analysis, 31 patients had experienced a PFS event (16 in the placebo group). Adjusted analyses by both Intention-to-treat (HR=1.10 [95%CI 0.51-2.38], p=0.81) and per-protocol (HR=1.15 [95% CI 0.51-2.62], p=0.73) indicated no benefit for PFS. The most common grade 3 or worse adverse events were skin rash (three [20%] of 15 patients with available data in the AZD8931 group vs none of 16 patients in the placebo group) and diarrhoea (one [7%] vs one [6%]).</p><p> Conclusions: The MAMS trial design for FOCUS4 has demonstrated efficiency and effectiveness in trial outcome delivery, informing the decision to proceed or stop clinical evaluation of a targeted therapy within a molecularly defined cohort of patients. The overarching FOCUS4 trial is now poised to open a replacement arm in the all wild type cohort.</p> |
| first_indexed | 2024-03-06T18:10:22Z |
| format | Journal article |
| id | oxford-uuid:02cda4d2-7789-4372-ad71-dd4145a107be |
| institution | University of Oxford |
| last_indexed | 2024-03-06T18:10:22Z |
| publishDate | 2017 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:02cda4d2-7789-4372-ad71-dd4145a107be2022-03-26T08:42:46ZInhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised trialJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:02cda4d2-7789-4372-ad71-dd4145a107beSymplectic Elements at OxfordElsevier2017Adams, RBrown, EBrown, LButler, RFalk, SFisher, DKaplan, RQuirke, PRichman, SSamuel, LSeligmann, JSeymour, MShiu, KKWasan, HWilson, RMaughan, T<p>Background: There has been a significant change in trials methodology for solid tumours, in response to our greater understanding of cancer biology. FOCUS4 is a phase II/III trial programme testing targeted agents in patients with advanced colorectal cancer (CRC) in molecularly stratified cohorts. Here we present the first results testing the hypothesis that combined Her 1,2,3 signal inhibition, using the tyrosine kinase inhibitor AZD8931, will control growth of ‘all wildtype’ tumours.</p><p> Methods: FOCUS4-D includes patients with newly diagnosed advanced or metastatic colorectal cancer whose tumour is BRAF, PIK3CA, KRAS & NRAS wildtype. Following 16 weeks of first-line therapy, patients with stable or responding tumours were randomised to oral AZD8931 (40mg bd) or placebo. Randomisation was done using minimisation with a random element of 20%, with minimisation factors were of randomising hospital site, site of primary tumour, WHO performance status, 16-week CT scan result, number of metastatic sites, and first-line chemotherapy regimen. The primary outcome was progression-free-survival (PFS) according to RECIST v1.1 criteria, pre-specified to be analysed by intention-to-treat. Pre-planned interim analyses were agreed using MAMS trial design methodology triggered by occurrence of PFS events in the placebo group. This trial is registered, number ISRCTN 90061546.</p><p> Results: 32 patients were randomised between 01/2014 and 03/2016. Patients were balanced for baseline characteristics. At the first pre-planned interim analysis, the IDMC recommended closure of FOCUS4-D on grounds of lack of activity. At final analysis, 31 patients had experienced a PFS event (16 in the placebo group). Adjusted analyses by both Intention-to-treat (HR=1.10 [95%CI 0.51-2.38], p=0.81) and per-protocol (HR=1.15 [95% CI 0.51-2.62], p=0.73) indicated no benefit for PFS. The most common grade 3 or worse adverse events were skin rash (three [20%] of 15 patients with available data in the AZD8931 group vs none of 16 patients in the placebo group) and diarrhoea (one [7%] vs one [6%]).</p><p> Conclusions: The MAMS trial design for FOCUS4 has demonstrated efficiency and effectiveness in trial outcome delivery, informing the decision to proceed or stop clinical evaluation of a targeted therapy within a molecularly defined cohort of patients. The overarching FOCUS4 trial is now poised to open a replacement arm in the all wild type cohort.</p> |
| spellingShingle | Adams, R Brown, E Brown, L Butler, R Falk, S Fisher, D Kaplan, R Quirke, P Richman, S Samuel, L Seligmann, J Seymour, M Shiu, KK Wasan, H Wilson, R Maughan, T Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised trial |
| title | Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised trial |
| title_full | Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised trial |
| title_fullStr | Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised trial |
| title_full_unstemmed | Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised trial |
| title_short | Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised trial |
| title_sort | inhibition of egfr her2 and her3 signalling in patients with colorectal cancer wild type for braf pik3ca kras and nras focus4 d a phase 2 3 randomised trial |
| work_keys_str_mv | AT adamsr inhibitionofegfrher2andher3signallinginpatientswithcolorectalcancerwildtypeforbrafpik3cakrasandnrasfocus4daphase23randomisedtrial AT browne inhibitionofegfrher2andher3signallinginpatientswithcolorectalcancerwildtypeforbrafpik3cakrasandnrasfocus4daphase23randomisedtrial AT brownl inhibitionofegfrher2andher3signallinginpatientswithcolorectalcancerwildtypeforbrafpik3cakrasandnrasfocus4daphase23randomisedtrial AT butlerr inhibitionofegfrher2andher3signallinginpatientswithcolorectalcancerwildtypeforbrafpik3cakrasandnrasfocus4daphase23randomisedtrial AT falks inhibitionofegfrher2andher3signallinginpatientswithcolorectalcancerwildtypeforbrafpik3cakrasandnrasfocus4daphase23randomisedtrial AT fisherd inhibitionofegfrher2andher3signallinginpatientswithcolorectalcancerwildtypeforbrafpik3cakrasandnrasfocus4daphase23randomisedtrial AT kaplanr inhibitionofegfrher2andher3signallinginpatientswithcolorectalcancerwildtypeforbrafpik3cakrasandnrasfocus4daphase23randomisedtrial AT quirkep inhibitionofegfrher2andher3signallinginpatientswithcolorectalcancerwildtypeforbrafpik3cakrasandnrasfocus4daphase23randomisedtrial AT richmans inhibitionofegfrher2andher3signallinginpatientswithcolorectalcancerwildtypeforbrafpik3cakrasandnrasfocus4daphase23randomisedtrial AT samuell inhibitionofegfrher2andher3signallinginpatientswithcolorectalcancerwildtypeforbrafpik3cakrasandnrasfocus4daphase23randomisedtrial AT seligmannj inhibitionofegfrher2andher3signallinginpatientswithcolorectalcancerwildtypeforbrafpik3cakrasandnrasfocus4daphase23randomisedtrial AT seymourm inhibitionofegfrher2andher3signallinginpatientswithcolorectalcancerwildtypeforbrafpik3cakrasandnrasfocus4daphase23randomisedtrial AT shiukk inhibitionofegfrher2andher3signallinginpatientswithcolorectalcancerwildtypeforbrafpik3cakrasandnrasfocus4daphase23randomisedtrial AT wasanh inhibitionofegfrher2andher3signallinginpatientswithcolorectalcancerwildtypeforbrafpik3cakrasandnrasfocus4daphase23randomisedtrial AT wilsonr inhibitionofegfrher2andher3signallinginpatientswithcolorectalcancerwildtypeforbrafpik3cakrasandnrasfocus4daphase23randomisedtrial AT maughant inhibitionofegfrher2andher3signallinginpatientswithcolorectalcancerwildtypeforbrafpik3cakrasandnrasfocus4daphase23randomisedtrial |